HIV medications HIV medication and schedule plan
|
|
- Corey Hunter
- 6 years ago
- Views:
Transcription
1 Living with HIV (human immunodeficiency virus) It may be scary to find out that you re HIV-positive or have AIDS. Coping with this news may be difficult. Although HIV is a serious infection, people with HIV or AIDS are living longer, healthier lives. Several treatment options may slow the rate at which HIV weakens your immune system. Because it is important for you to learn as much as you can about HIV, we re providing you with this medication resource guide to help you live well with your condition. HIV and medications This booklet discusses current antiretroviral agents. It s not intended to guide treatment decisions or strategies. Decisions about when to initiate treatment, how many medications to use, when to change treatment, or whether a treatment change involves substitution or complete replacement of medications are very complex and need to be made with the advice of an HIV/AIDS experienced practitioner. You and your doctor will determine the best time to start treatment. When to take anti-hiv (also called antiretroviral) medications depends on your overall health, the amount of virus in your blood (viral load), and how well your immune system is working. In some situations, you may not need to take anti-hiv medications just because you re HIV-positive. Before starting anti-hiv medications, you, your doctor, and others on your health care team will consider four factors: your symptoms of advanced HIV disease your viral load your CD4 count your willingness to take the medications prescribed as they have been prescribed These four factors likely will change with time, so your clinician will want to check these labs and your health status regularly. Also, before you begin an HIV treatment regimen, there are several steps you can take to help you follow through with taking the medications: Talk with your doctor about your treatment regimen. Get a written copy of your treatment plan that lists each medication, when and how much to take, and if it must be taken with food or on an empty stomach. Understand the importance of adhering to the plan. Be honest about personal issues that may affect your adherence and speak candidly with your HIV care team about these issues. Sticking to a plan of treatment may be harder for people dealing with substance abuse or alcoholism, unstable housing, mental illness, or other life challenges (including financial issues). Develop a plan that works for you. Identify the activities you normally do at the times that you will be taking your medication. People who arrange their medication schedule around their daily routines follow through with their treatment plans better than those who do not. Consider a "dry run." Practice your treatment regimen using vitamins, jelly beans, or mints. This will help you determine ahead of time which doses might be difficult to take correctly. Some people with HIV are placed on one or more combinations of medications. On the following pages, you ll find a list of antiretroviral medications used to combat HIV, their description, possible side effects, and a schedule plan. You can write information about your medications and schedule on this form. You can select the of the medication you are taking, enter the number of pills you take at different times throughout the day, and add any notes that might be helpful to you in taking your medications or communicating with your health care team. Please note that the list of medications and their side effects is not exhaustive and each person is different. 2009, The Permanente Medical Group, Inc. All rights reserved. 1
2 Protease inhibitors (PIs) Protease inhibitors (PIs) are a class of anti-hiv drugs. Protease inhibitors prevent T-cells that have been infected with HIV from producing new copies of the virus. When one PI is used in combination with other anti-hiv drugs usually a total of at least 3 drugs then combination therapy can block the replication of HIV in a person's blood. Aptivus (tipranavir) Take with light meal or snack 250 mg diarrhea, stomach pain, tiredness, headache Crixivan (indinavir) Invirase (saquinavir) Kaletra (lopinavir plus ritonavir) No food two hours before or one hour after dosing, or with a light, low-fat snack Within 2 hours after a full meal With or without food 400 mg 500 mg 200/50 mg Kidney stones, nausea, vomiting, diarrhea, stomach discomfort, headache, insomnia, rash, back pain Nausea, diarrhea, stomach discomfort, insomnia, headache Diarrhea, nausea, feeling weak/tired Lexiva (fosamprenavir) 700 mg Rash, diarrhea, nausea, vomiting Norvir (ritonavir) With food if possible Refrigerate (especially in warmer weather or climates) 100 mg Prezista (darunavir) With a meal 600 mg Reyataz (atazanavir) Viracept (nelfinavir) Take with light meal Take with a meal or light snack 150 mg 300 mg 625 mg diarrhea, loss of appetite, stomach discomfort, oral tingling and numbness Diarrhea, nausea, headache, nasopharyngitis, rash Headache, pain/tingling in the arms and legs, nausea, diarrhea, rash Diarrhea, nausea, stomach discomfort, gas, rash 2009, The Permanente Medical Group, Inc. All rights reserved. 2
3 Nucleoside reverse transcriptase inhibitors (NRTIs) NRTIs are a class of anti-hiv drugs. When NRTIs are used in combination with other anti-hiv drugs usually a total of at least 3 drugs then combination therapy can block the replication of HIV in a person's blood. They are sometimes referred to as nucleoside analogues or "nukes" for short, and help prevent HIV from replicating into DNA that can then damage healthy lymphocytes (T-cells, or CD4/CD8 cells). Combivir (zidovudine plus lamivudine Emtriva (emtricitabine) Epivir (lamivudine) 150 mg 300 mg Epzicom (abacavir plus lamivudine Retrovir (zidovudine) [AZT] Trizivir (zidovudine plus lamivudine plus abacavir Truvada (tenofovir plus emtricitabine 100 mg 300 mg Viread (tenofovir) 300 mg Videx (didanosine) Take on empty 100 mg stomach, at least 30 minutes before or 2 hours after eating Videx EC (didanosine) Zerit (stavudine) [d4t] Empty stomach Avoid alcohol 125 mg 250 mg 400 mg 40 mg Ziagen (abacavir) 300 mg 600 mg Nausea, loss of appetite, headache, fatigue, stomach discomfort Headache, diarrhea, nausea, rash Nausea diarrhea, loss of appetite Nausea, stomach discomfort, headache, insomnia Fever, malaise, nausea, diarrhea, abdominal pain, sore throat, cough, shortness of breath, rash diarrhea, intestinal gas diarrhea, intestinal gas Numbness, tingling, pain in hands or feet, nausea, diarrhea, vomiting, headache, rash Numbness, tingling, pain in hands or feet, nausea, diarrhea, vomiting, headache, rash Numbness, tingling, pain in hands or feet, nausea, diarrhea, vomiting, headache, rash diarrhea, loss of appetite, insomnia 2009, The Permanente Medical Group, Inc. All rights reserved. 3
4 Non-nucleoside reverse transcriptase inhibitors (NNRTIs) NNRTIs are a class of anti-hiv drugs. When one NNRTI is used in combination with other anti-hiv drugs usually a total of 3 drugs then combination therapy can block the replication of HIV in a person's blood. NNRTIs, sometimes referred to as nonnucleoside analogues or "non-nukes" for short, prevent healthy T-cells in the body from becoming infected with HIV. When HIV infects a cell in a person's body, it copies its own genetic code into the cell's DNA. By doing this, the cell is then "programmed" to create new copies of HIV. HIV's genetic material is in the form of RNA. In order for it to infect T-cells, it must first convert its RNA into DNA. HIV's reverse transcriptase enzyme is needed to perform this process. Reverse transcriptase is an enzyme that HIV brings along with itself so that the virus can use the nucleic acid in the CD4 cells it is infecting to change itself from an RNA virus to a DNA virus. NNRTIs attach themselves to reverse transcriptase and prevent the enzyme from converting RNA into DNA. In turn, HIV's genetic material cannot be incorporated into the healthy genetic material of the cell, thus preventing the cell from producing new virus. Edurant (Rilpivirine) With a meal 25 mg Rash, depression or mood swings, headache, vivid dreams Intelence (etravirine) With a meal 100 mg Rash, nausea, diarrhea, fatigue Rescriptor (delavirdine) Take at least 1 hour apart from buffered Videx (ddi) or antacids Sustiva (efavirenz) Take on empty stomach 600 mg Viramune (nevirapine) Rash, headache, fatigue, stomach upset Rash, vivid dreams, dizziness, confusion, insomnia, stomach discomfort Rash, stomach upset, headache, fatigue 2009, The Permanente Medical Group, Inc. All rights reserved. 4
5 Fusion inhibitors Entry (and fusion) inhibitors work by preventing HIV from entering healthy T-cells in the body. They work differently from many of the approved anti-hiv drugs the protease inhibitors (PIs), the nucleoside reverse transcriptase inhibitors (NRTIs), and the nonnucleoside reverse transcriptase inhibitors (NNRTIs), which are active against HIV after it has infected a T-cell. Entry inhibitors work by attaching themselves to proteins on the surface of T-cells or proteins on the surface of HIV. In order for HIV to bind to T-cells, the proteins on HIV's outer coat must bind to the proteins on the surface of T-cells. Entry inhibitors prevent this from happening. They still must be used, though, with other active anti-hiv drugs, usually in combinations of at least 3 drugs. Fuzeon (enfuvirtide) [T-20] 90 mg (1 ml solution) subcutaneous injection Pain, inflammation, bumps, itchiness, bruising 2009, The Permanente Medical Group, Inc. All rights reserved. 5
6 Full combination pills These are three drugs put into one combination pill that can possibly serve as your full regimen. However, in the United States, most patients cannot take these medications as their only treatment against HIV because the HIV in their body is already resistant to at least one part of the combination pill, rendering it ineffective. Consult with your clinician about potential resistance before starting any of these medications. Atripla (tenofovir plus emtricitabine plus efavirenz Empty stomach See above for all three of these drugs Complera (tenofovir plus emtricitabine plus rilpivirine With a meal See above for all three of these drugs Trizivir (zidovudine plus lamivudine plus abacavir See above for all three of these drugs 2009, The Permanente Medical Group, Inc. All rights reserved. 6
7 CCR5 antagonists CCR5 antagonists work by preventing HIV from attaching to the cells in your body. They block the virus from attaching to a coreceptor. If the virus cannot attach to the CCR5 co-receptor, it cannot get in and infect the cell. However, not all HIV needs CCR5 coreceptors to infect cells; in fact, most HIV-positive patients with advanced disease do not have virus that needs CCR5 co-receptors. Your doctor will order a test before prescribing CCR5 antagonists to make sure your virus needs CCR5 co-receptors to work (called CCR5 tropic ). The CCR5 antagonists still must be used, though, with other active anti-hiv drugs, usually in combinations of at least 3 drugs. Selzentry (maraviroc) 150 mg 300 mg Cough, fever, upper respiratory tract infections, rash, musculoskeletal symptoms, abdominal pain and dizziness 2009, The Permanente Medical Group, Inc. All rights reserved. 7
8 Integrase inhibitors Integrase inhibitors work by preventing HIV from being incorporated in the cell s nucleus They still must be used, though, with other active anti-hiv drugs, usually in combinations of at least 3 drugs. Isentress (raltegravir) 400 mg Nausea, headache, diarrhea, fever, muscle aches 2009, The Permanente Medical Group, Inc. All rights reserved. 8
9 Helpful terms AIDS: Acquired Immune Deficiency Syndrome. AIDS is the most severe form of HIV infection. HIV-infected patients are diagnosed with AIDS when their CD4 cell count falls (below 200 cells/mm3) or if they develop an AIDS-defining illness (an illness that is very unusual in someone who is not HIV-positive). Antiretroviral: A medication that interferes with replication of retroviruses. HIV is a retrovirus. CD4 count: CD4 cells, also called T-cells or CD4+ T-cells, are white blood cells that fight infection. HIV destroys CD4 cells, making it harder for your body to fight infections. A CD4 count is the number of CD4 cells in a sample of blood. Drug resistance: HIV can mutate (change form) while a person is taking anti-hiv medication. This may result in HIV that cannot be controlled with certain medications. Viral load: The amount of HIV in a sample of blood. References AIDSinfo, aidsinfo.nih.gov Kaiser Permanente (San Francisco) HIV/AIDS Medications Guide AIDSMeds.com, aidsmeds.com * This list of possible side effects may not be exhaustive. You should discuss possible side effects with your physician. Last updated: April 13, 2009 The information presented here is not intended to diagnose health problems or to take the place of information or medical care you receive from your physician or other medical professional. If you have persistent health problems, or if you have additional questions, please consult your physician or other medical professional. 2009, The Permanente Medical Group, Inc. All rights reserved. 9
HIV Drugs and the HIV Lifecycle
HIV Drugs and the HIV Lifecycle Together, we can change the course of the HIV epidemic one woman at a time. #onewomanatatime #thewellproject All HIV drugs work by interrupting different steps in HIV's
More informationTHE HIV LIFE CYCLE. Understanding How Antiretroviral Medications Work
THE HIV LIFE CYCLE Understanding How Antiretroviral Medications Work DEFINITIONS Host: The animal or cell that another organism lives in. In HIV human CD4 T-cells are the host for HIV. Nucleus: The core
More informationNorthwest AIDS Education and Training Center Educating health care professionals to provide quality HIV care
Northwest AIDS Education and Training Center Educating health care professionals to provide quality HIV care www.nwaetc.org The Northwest AIDS Education and Training Center (NW AETC), located at the University
More informationHIV MEDICATIONS AT A GLANCE. Atripla 600/200/300 mg tablet tablet daily. Complera 200/25/300 mg tablet tablet daily
HIV MEDICATIONS AT A GLANCE Generic Name Trade Name Strength DIN Usual Dosage Single Tablet Regimen (STR) Products Efavirenz/ Emtricitabine/ rilpivirine/ elvitegravir/ cobicistat/ alafenamide Emtricitabine/
More informationPage 1 of 5 ENLGLISH / ESPAÑOL / PORTUGUÉS / FRANÇAIS Share 3 Drug Chart for HIV Treatment CURRENT EDITION ABOUT SENSE BACK ISSUES MSMGF HOME CONTACT US There are a number of antiretroviral (ARV) medications
More informationWOMENS INTERAGENCY HIV STUDY ANTIRETROVIRAL DOSAGE FORM SECTION A. GENERAL INFORMATION
WOMENS INTERAGENCY HIV STUDY ANTIRETROVIRAL DOSAGE FORM SECTION A. GENERAL INFORMATION A1. PARTICIPANT ID: ENTER NUMBER HERE - - - ONLY IF ID LABEL IS NOT AVAILABLE A2. VISIT #: A3. VERSION DATE: 1 0 /
More informationWOMEN'S INTERAGENCY HIV STUDY METABOLIC STUDY: MS01 SPECIMEN COLLECTION FORM
WOMEN'S INTERAGENCY HIV STUDY METABOLIC STUDY: MS01 SPECIMEN COLLECTION FORM ID LABEL HERE ---> VERSION DATE 10/01/07 - - - VISIT #: FORM COMPLETED BY: A1. DATE OF BLOOD DRAW: / / M D Y A2. Do you take
More informationHIV THERAPY STRATEGIES FOR THIRD LINE. issues to consider when faced with few drug options
STRATEGIES FOR THIRD LINE HIV THERAPY issues to consider when faced with few drug options A PUBLICATION FROM Information, Inspiration and Advocacy for People Living With HIV/AIDS MAY 2008 Most people living
More informationHIV THERAPY STRATEGIES FOR FIRST LINE. issues to think about when going on therapy for the first time
STRATEGIES FOR FIRST LINE HIV THERAPY issues to think about when going on therapy for the first time A PUBLICATION FROM Information, Inspiration and Advocacy for People Living With HIV/AIDS MAY 2008 Deciding
More informationMEDICAL COVERAGE GUIDELINES ORIGINAL EFFECTIVE DATE: 03/07/18 SECTION: DRUGS LAST REVIEW DATE: 02/19/19 LAST CRITERIA REVISION DATE: ARCHIVE DATE:
FUZEON (enfuvirtide) Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical devices and drugs
More informationOctober 26-28: Training Day 1
Peer Linkage and Re-Engagement of HIV- Positive Women of Color October 26-28: Training Day 1 Peer Linkage and Re -Engagement of HIV - Positive Women of Color Convening Training Trainers Today: Alicia Downes
More information0.14 ( 0.053%) UNAIDS 10% (94) ( ) (73-94/6 ) 8,920
0.14 UNAIDS 0.053% 2 250 60 10% 94 73 20 73-94/6 8,920 12 43 Public Health Service Task Force Recommendations 5-10% for Use of Antiretroviral Drugs in 10-20% Pregnant HIV-1-Infected Women for Maternal
More informationHuman Immunodeficiency Virus (HIV) and Acquired Immune Deficiency Syndrome (AIDS) in the Long Term Care Setting Part 2: HIV Medications
Human Immunodeficiency Virus (HIV) and Acquired Immune Deficiency Syndrome (AIDS) in the Long Term Care Setting Part 2: HIV Medications Carrie Allen PharmD, CGP, BCPS, BCPP, CCHP Overview - Part 2: HIV
More informationAntiretroviral Dosing in Renal Impairment
Protease Inhibitors (PIs) Atazanavir Reyataz hard capsules 300 mg once daily taken with ritonavir 100 mg once daily No dosage adjustment is needed for atazanavir in renal impairment Atazanavir use in haemodialysis
More informationNothing to disclose.
Lisa G. Winston, MD University of California, San Francisco San Francisco General Hospital HIV UPDATE FOR THE PRIMARY CARE PROVIDER Nothing to disclose. 1 Outline Epidemiology Screening / testing for HIV
More informationMedscape's Antiretroviral Pocket Guide for the Treatment of HIV Infection
Table 3. Characteristics of Nucleoside Reverse Transcriptase Inhibitors (NRTIs) Generic Name (Abbreviation) / Trade Name Abacavir (ABC) / Ziagen Trizivir with ZDV + 3TC Epzicom with 3TC Didanosine (ddi)
More informationNobel /03/28. HIV virus and infected CD4+ T cells
Mechanism of HIV drug resistance. Rodrigo Brindeiro / Amilcar Tanuri Laboratório de Virologia Molecular UFRJ 2 -Asso ciate Research Scientist, Internatio nal Center fo r Aids Care and Treatment Programs-ICAP,
More informationANTIRETROVIRAL TREATMENTS (Part 1of
CCR5 CO-RECEPTOR ANTAGONISTS maraviroc (MVC) Selzentry 25mg, 75mg, FUSION INHIBITORS 20mg/mL ANTIRETROVIRAL TREATMENTS (Part 1of 5) oral soln enfuvirtide (ENF, T-20) Fuzeon 90mg/mL pwd for SC inj after
More informationDaclatasvir (Daklinza ) Drug Interactions with HIV Medications
Daclatasvir/Sofosbuvir (Daklinza /Sovaldi TM ) Drug Interactions A Quick Guide for Clinicians April 2017 John J Faragon, PharmD, BCPS, AAHIVP Mechanism of Action and Route of Metabolism for Daclatasvir
More informationHIV and YOU. Special 2008 Update!
HIV and YOU Special 2008 Update! HIV and You Special 2008 Update! In this booklet, you ll see words in bold, red type. Go to the Glossary on the back cover to find out what these words mean. WRITERS AND
More informationAdherence Strategies for Older Adults. AIDS Community Research Initiative of America (ACRIA)
Adherence Strategies for Older Adults AIDS Community Research Initiative of America (ACRIA) June 2008 Modular Objectives By the end of the module, participants will be able to: Define adherence Be able
More informationHIV Management Update 2015
9/30/15 HIV Management Update 2015 Larry Pineda, PharmD, PhC, BCPS Visiting Assistant Professor Pharmacy Practice and Administrative Science ljpineda@salud.unm.edu Pharmacist Learning Objectives Describe
More informationREIMBURSEMENT STATUS OF HIV MEDICATIONS IN ONTARIO
REIMBURSEMENT STATUS OF HIV MEDICATIONS IN ONTARIO Ont. Drug Distr. Ontario Drug Benefit/Trillium: Other Formulary (F/A) Limited Use (Section 16) Antiretrovirals AZT 100 mg capsules NRTIs (single): Abacavir,
More informationFluconazole dimenhydrinate, diphenhydramine. Raltegravir or dolutegravir with antacids
Supportive therapy Summary of interactions Table 1. Summary of potential interactions between antiretroviral agents and supportive therapy Interactions with enzyme inhibitors (protease inhibitors and elvitegravir/cobicistat)
More informationADAP Monitoring Provider Prescribing Patterns. Amanda Bowes, NASTAD Christine Rivera and Dr. Charles Gonzalez, NYS AIDS Institute
ADAP Monitoring Provider Prescribing Patterns Amanda Bowes, NASTAD Christine Rivera and Dr. Charles Gonzalez, NYS AIDS Institute WEBINAR ETIQUETTE All questions or comments can be shared either via the
More informationNON-OCCUPATIONAL POST EXPOSURE PREVENTION. when you think you were exposed to hiv within the past three days
NON-OCCUPATIONAL POST EXPOSURE PREVENTION when you think you were exposed to hiv within the past three days A PUBLICATION FROM Information, Inspiration and Advocacy for People Living With HIV/AIDS MAY
More informationA Fatal Imbalance. Tropical diseases: 18 new drugs (incl. 8 for malaria) 1.3% 21 new drugs for neglected diseases. Tuberculosis: 3 new drugs
ADDRESSING GAPS IN INNOVATION FOR NEGLECTED PATIENTS: DNDI ANDPEDIATRIC HIV/AIDS Rachel Cohen, Regional Executive Director, DNDi North America Proposals for a Global Innovation System that Responds to
More informationAntiretrovial Crushable/Liquid Formulation Chart
Antiretrovial Crushable/Liquid Formulation Chart Eliza Dollard, PharmD; Nafeesa Chin-Beckford, PharmD; Laura Aragon, PharmD Last Updated: 04/2016 Agent How Supplied Crushable Status **Products listed in
More informationContinuing Education for Pharmacy Technicians
Continuing Education for Pharmacy Technicians HIV/AIDS TREATMENT Michael Denaburg, Pharm.D. Birmingham, AL Objectives: 1. Identify drugs and drug classes currently used in the management of HIV infected
More informationCOMPREHENSIVE ANTIRETROVIRAL TABLE: ADULT DOSING, DOSAGE FORM MODIFICATIONS, ADVERSE REACTIONS and INTERACTION POTENTIAL
Generic Name COMPREHENSIVE ANTIRETROVIRAL TABLE: NUCLOESIDE/TIDE REVERSE TRANSCRIPTASE INHIBITORS (N(t)RTIs) Abacavir ABC (Ziagen) Didanosine ddi (Videx EC) Emtricitabine FTC (Emtriva) Lamivudine 3TC (Epivir)
More informationALABAMA S ADAP FORMULARY OFFERS 117 MEDICATIONS
ALABAMA S ADAP FORMULARY OFFERS 117 MEDICATIONS - 2014 Alabama s ADAP formulary offers a minimum of one medication from each HIV antiretroviral class approved by the U.S. Food and Drug Administration (FDA).
More informationDrug Treatment Program Update
Drug Treatment Program Update As of March 211 Drug Treatment Program Update A key component of the Centre s mandate is to monitor the impact of HIV/AIDS on British Columbia. The Centre provides essential
More informationcontinuing education for pharmacists
continuing education for pharmacists HIV/AIDS: Overview and Resources for Pharmacists Mona T. Thompson, R.Ph., PharmD Volume XXXIII, No. 9 Dr. Mona T. Thompson has no relevant financial relationships to
More informationHIV Pharmacology 101ish - 202ish: New HIV Clinicians Workshop
HIV Pharmacology 101ish - 202ish: New HIV Clinicians Workshop Parya Saberi, PharmD, MAS The Medical Management of HIV/AIDS December 2012 Objectives What are commonly used ARVs and where do they work in
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 9 May 2012
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 9 May 2012 EDURANT 25 mg film-coated tablets B/30 (CIP code: 219 472-9) Applicant: JANSSEN-CILAG rilpivirine ATC code
More informationP.I. Perspective. December 2008, Issue #47. Information, Inspiration and Advocacy for People Living with HIV/AIDS
P.I. Perspective December 2008, Issue #47 Information, Inspiration and Advocacy for People Living with HIV/AIDS This issue of PI Perspective represents Project Inform s coverage of the joint 2008 ICAAC
More informationImportant Safety Information About TRUVADA to Reduce the Risk of Getting Human Immunodeficiency Virus 1 (HIV-1) Infection
Important Safety Information About TRUVADA to Reduce the Risk of Getting Human Immunodeficiency Virus 1 (HIV-1) Infection This booklet is for adults taking TRUVADA to reduce the risk of getting HIV-1 infection.
More informationAppropriate Use & Safety Edits
Appropriate Use & Safety Edits Envolve Pharmacy Solutions provides a variety of safety edits to promote the use of the right medication, in the right patient, at the right time. These edits are routinely
More informationBHIVA ART Guideline 2014 update: SEARCH PROTOCOL: main databases search
BHIVA ART Guideline 2014 update: SEARCH PROTOCOL: main databases search Search 1 :When to Initiate ART Covers Questions 1-5 including to prevent transmission Component Description Review area Objectives
More informationGenotyping and Drug Resistance in Clinical Practice. Case Studies
Genotyping and Drug Resistance in Clinical Practice Case Studies 12/02 40 year old Hispanic male Dx with HIV 1995 + Hx of PCP > 1x, HepC Medication history: AZT, Crixivan, Videx EC, Sustiva, Zerit, Ziagen,
More informationWhat is the most important information I should know about tenofovir? What should I discuss with my healthcare provider before taking tenofovir?
1 of 6 6/10/2016 4:33 PM Generic Name: tenofovir (ten OF oh vir) Brand Name: Viread What is tenofovir? Tenofovir is an antiviral medicine that prevents human immunodeficiency virus (HIV) or hepatitis B
More informationAn HIV Update Jan Clark, PharmD Specialty Practice Pharmacist
An HIV Update - 2019 Jan Clark, PharmD Specialty Practice Pharmacist 2 The goal of this program is to provide a review and update of HIV care and to provide a forum for discussing the current local and
More informationCOMPREHENSIVE ANTIRETROVIRAL TABLE: ADULT DOSING**, DOSAGE FORM MODIFICATIONS, ADVERSE REACTIONS and INTERACTION POTENTIAL
COMPREHENSIVE ANTIRETROVIRAL TABLE: NUCLOESIDE/TIDE REVERSE TRANSCRIPTASE INHIBITORS (N(t)RTIs) Abacavir ABC (Ziagen) Didanosine ddi (Videx EC) Emtricitabine FTC (Emtriva) Lamivudine 3TC (Epivir) Stavudine
More informationHuman Immunodeficiency Virus Infection A Modern Day Epidemic
Human Immunodeficiency Virus Infection A Modern Day Epidemic Frank Romanelli, PharmD, MPH, BCPS Assistant Dean and Associate Professor of Pharmacy Clinical Specialist in HIV/AIDS University of Kentucky
More informationJULUCA (dolutegravir sodium-rilpivirine hydrochloride) oral tablet
JULUCA (dolutegravir sodium-rilpivirine hydrochloride) oral tablet Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific
More informationHIV Infection & AIDS in Low- and Middle-Income Countries
GUIDE TO INFECTION CONTROL IN THE HOSPITAL CHAPTER 25: HIV Infection & AIDS in Low- and Middle-Income Countries Author P. Van de Perre, MD, PhD Chapter Editor Michelle Doll, MD, MPH Topic Outline Key Issues
More informationAddressing Pediatric Needs of the Most Neglected: next steps
Addressing Pediatric Needs of the Most Neglected: next steps An updated overview of DNDi Pediatric Focus Nathalie Strub Wourgaft (Medical Director) Janice Lee (HIV Pediatric Clinical Manager) A Fatal Imbalance
More informationMidwestern Underwriting Conference 2016
UNDERWRITING HIV: THE FAIRY TALE HAS BECOME REALITY Midwestern Underwriting Conference 2016 Jean-Marc Fix, FSA, MAAA VP, R&D, Optimum Re Insurance Co. AGENDA Where are we with HIV? The risk The ideal case
More informationApproach for the Newly Diagnosed HIV Positive Patient
Approach for the Newly Diagnosed HIV Positive Patient Jason E. Farley, PhD, MPH, ANP-BC, FAAN, AACRN Associate Professor & NP, Johns Hopkins University School of Nursing & Medicine Director, AETC Adult-Gerontology
More informationACTHIV 2018: A State-of-the-Science Conference for Frontline Health Professionals
Antiretroviral Medications: What you need to know Jason J. Schafer, PharmD, MPH, BCPS, AAHIVP Associate Professor, Department of Pharmacy Practice Jefferson College of Pharmacy, Thomas Jefferson University
More informationIndustry Data Request
Industry Data Request Purpose: reported data will be used internally to populate patient forecasting models that are used for business planning. Business planning includes stock requirement forecasts,
More informationtreatment passport 1
treatment passport 1 Why keep a treatment history? Keeping a short record of your treatment history can help in many ways. It can help you understand your health and treatment. It can help if your doctor
More informationOB/GYN CHART REVIEW DRAFT: NOT FOR DISTRTIBUTION
OB/GYN CHART REVIEW A summary of OB/GYN clinical chart review results designed to monitor the quality of care provided by a Ryan White funded OB/GYN primary care site as part of the Atlanta EMA s quality
More informationFORMULARY Virginia (VA) AIDS Drug Assistance Program (ADAP) LAST UPDATED: December At a Glance: VA ADAP Formulary
At a Glance: VA ADAP Formulary Nucleoside/Nucleotide Reverse Transcriptase Inhibitors (NRTIs) Non Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) Multi Class Combination Agents Protease Inhibitors
More informationOverview of HIV WRAIR- GEIS 'Operational Clinical Infectious Disease' Course
Overview of HIV WRAIR- GEIS 'Operational Clinical Infectious Disease' Course UNCLASSIFIED Acknowledgments - Dr. Christina Polyak - Dr. Julie Ake Disclaimer The views expressed in this presentation are
More informationSimplifying HIV Treatment Now and in the Future
Simplifying HIV Treatment Now and in the Future David M. Hachey, Pharm.D., AAHIVP Professor Idaho State University Department of Family Medicine Nothing Disclosure 1 Objectives List current first line
More informationPROGRESSIVE MULTI-FOCAL LEUKOENCEPHALOPATHY
PROGRESSIVE MULTI-FOCAL LEUKOENCEPHALOPATHY learn about the symptoms, diagnosing and treating this relatively rare brain condition associated with aids A PUBLICATION FROM Information, Inspiration and Advocacy
More informationNew Frontiers for Treatment Strategies for HIV Care
New Frontiers for Treatment Strategies for HIV Care Eric S. Daar, MD Chief, Division of HIV Medicine Harbor-UCLA Medical Center Professor of Medicine David Geffen School of Medicine at UCLA Disclosures:
More informationThe ART of Antiretroviral Therapy in Critically-ill Patients with HIV
The ART of Antiretroviral Therapy in Critically-ill Patients with HIV Tyler Finocchio, PharmD, BCPS PGY2 Critical Care Pharmacy Resident Avera McKennan Hospital & University Health Center February 10 th,
More informationQuick Reference Guide to Antiretrovirals. Guide to Antiretroviral Agents
Author: Malte Schütz, MD June 1, 2002 Quick Reference Guide to Antiretrovirals Regular updates to this publication are posted on the Medscape Web site at http://hiv.medscape.com/updates/quickguide. Please
More informationApproach to a Patient Newly Diagnosed with HIV, Including ART Basics Rajesh T. Gandhi, M.D.
Approach to a Patient Newly Diagnosed with HIV, Including ART Basics Rajesh T. Gandhi, M.D. Disclosures: grant support from Gilead, Roche, EBSCO Objectives Apply current guidelines to initial evaluation
More informationIndustry Request Integrase Inhibitors
Industry Request Integrase Inhibitors The objective of this request is to describe and understand the temporal changes in the prescribing practices of Integrese Inibitors (II) in AHOD cohort between 1/1/
More informationOverview of HIV. LTC Paige Waterman
Overview of HIV LTC Paige Waterman Outline Background and Epidemiology HIV Virology, Transmission, and Pathogenesis Acute HIV infection HIV Diagnostics Management of Health Care Personnel Exposed to HIV
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 3 November 2010
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 3 November 2010 ISENTRESS 400 mg, film-coated tablet B/60 (CIP code: 383 084-8) Applicant: MSD-CHIBRET raltegravir
More informationObjectives. HIV Treatment in Recently In 1996 the introduction of protease inhibitors decreasing the death rate of those infected by 50%.
Objectives Identify modes HIV transmission and methods of prevention. HIV Treatment in 2010 Lisa D. Inge, Pharm.D., BCPS, AAHIVE Assistant Director, Jacksonville Campus Clinical Assistant Professor University
More informationHIV Treatment Guidelines
HIV Treatment Guidelines Together, we can change the course of the HIV epidemic one woman at a time. #onewomanatatime #thewellproject What Are Treatment Guidelines? Issued by variety of global and country-based
More informationFLORIDA!A MEDICAID' Better Health Care for all Floridians. May
CHARLIE CRIST GOVERNOR FLORIDA!A MEDICAID' Better Health Care for all Floridians HOllY BENSON SECRETARY May 26. 2009 Policy Transmittal: HMO 09-01 Policy Transmittal: PS 09-01 RE: Year Thrcc PerFormance
More informationWorld AIDS Day Year-by-Year Milestones in HIV/AIDS. healthlibrary
World AIDS Day 2014 Year-by-Year Milestones in HIV/AIDS (Adapted from The POZ Timeline: Milestones in the HIV/AIDS Pandemic with additions compiled by Eric Brus, Director of HIV Health Promotion, AIDS
More informationHIV Treatment. Why do I need to know about HIV treatment?
HIV Treatment Why do I need to know about HIV treatment? As a person living with HIV, you have to decide which HIV treatment is right for you, using the best information available. The more informed you
More informationMEDICATION RELATED ISSUES IN THE HIV PATIENT. LEONARD SOWAH, MBChB, MPH, FACP
MEDICATION RELATED ISSUES IN THE HIV PATIENT LEONARD SOWAH, MBChB, MPH, FACP Overview Evalua;on and ini;al of a HIV pa;ent with respect to medica;ons Triaging of pa;ent to determine ideal follow up plan
More informationThe Annotated Bibliography of the UCSF HIV Solid Organ Transplantation Project. ARV Dosing in End Stage Renal Disease
The Annotated Bibliography of the UCSF HIV Solid Organ Transplantation Project ARV Dosing in End Stage Renal Disease 1. Jayasekara, D., Aweeka, F. T., Rodriguez, R., Kalayjian, R. C., Humphreys, M. H.,
More informationTerapia antirretroviral inicial y de rescate: Utilidad actual y futura de nuevos medicamentos
Terapia antirretroviral inicial y de rescate: Utilidad actual y futura de nuevos medicamentos (Antiretroviral Therapy Present and Future Prospects of Antiretroviral Drugs in Initial and Salvage Therapy)
More informationPOST-EXPOSURE PROPHYLAXIS, PRE-EXPOSURE PROPHYLAXIS, & TREATMENT OF HIV
POST-EXPOSURE PROPHYLAXIS, PRE-EXPOSURE PROPHYLAXIS, & TREATMENT OF HIV DISCLOSURE Relevant relationships with commercial entities none Potential for conflicts of interest within this presentation none
More informationP.I. Perspective. To nuke, or not to nuke? April 2007, Issue #43. Information, Inspiration and Advocacy for People Living with HIV/AIDS CONTENTS
P.I. Perspective April 2007, Issue #43 Information, Inspiration and Advocacy for People Living with HIV/AIDS To nuke, or not to nuke? CONTENTS 1 3 To Nuke, or Not to Nuke? 3 Reporting Adverse Medication
More informationHIV epidemiology since HIV in the United States. HIV Transmission
HIV epidemiology since 1999 8% increase in HIV diagnoses Men who have sex with men (MSM) increased 14% Heterosexual increased 10% IVDU decrease about 30% Young Black MSM 15% incidence HIV in the United
More informationSculpting a Better Regimen: The ART of HIV Medications
Sculpting a Better Regimen: The ART of HIV Medications Kelly Peddy, PharmD, MPA Clinical Pharmacy Specialist - Ambulatory Care Memorial Hospital of South Bend November 30, 2017 For HealthTrust Members
More informationRapid Review Response HIV Medication and Depression
Rapid Review Response HIV Medication and Depression Question: Is depression a side effect of anti-retroviral medications taken by people living with HIV? The issue and why it s important The Ontario HIV
More informationtreatment VIRAL SUPPRESSION SUPPORT ART IS THE ONLY WAY TO CONTROL HIV TIPS FOR TAKING ART ADHERENCE Benefits of ART Start Know Your ARVs today ARVs
treatment Benefits of ART Know Your ARVs Start ARVs today SUPPORT VIRAL SUPPRESSION TIPS FOR TAKING ART ART IS THE ONLY WAY TO CONTROL HIV ADHERENCE HIV: BASIC FACTS HIV stands for the Human Immunodeficiency
More information0% 0% 0% Parasite. 2. RNA-virus. RNA-virus
HIV/AIDS and Treatment Manado, Indonesia 16 november HIV [e] EDUCATION HIV is a 1. DNA-virus 2. RNA-virus 3. Parasite 0% 0% 0% DNA-virus RNA-virus Parasite HIV HIV is a RNA-virus. HIV is an RNA virus which
More informationPrinciples of HIV Drug Resistance: Resistance to New Drug Classes. Mark A Wainberg McGill University AIDS Centre Montreal, Quebec, Canada
Principles of HIV Drug Resistance: Resistance to New Drug Classes Mark A Wainberg McGill University AIDS Centre Montreal, Quebec, Canada Why Is It Important to Understand HIV Drug Resistance? 1. Resistance
More informationUnderstanding Viruses CHAPTER 38. Antiviral Agents. Understanding Viruses (cont'd) Viral Infections (cont'd) Viral Infections.
Understanding Viruses CHAPTER 38 Antiviral Agents Viral replication A virus cannot replicate on its own It must attach to and enter a host cell It then uses the host cell s energy to synthesize protein,
More informationAntiretroviral Pregnancy Registry
Preterm Birth, low birth weight and fetal antiretroviral exposure: Estimated gestational age and birth weight data from singleton live births, 1989 through 31 January 2009 K. Beckerman, J. Albano, M. Martinez-Tristani,
More informationHuman Immunodeficiency Virus (HIV)
HIV INFECTION! Human Immunodeficiency Virus (HIV) Infects human cells and causes gradual loss of immune system function, and these immune alterations predispose to the opportunistic infections, neoplasms,
More informationUnderstanding HIV Basics. Author: Tricia Smith, Canadian AIDS Treatment Information Exchange
P S Y C H O S O C I A L W E L L B E I N G S E R I E S Understanding HIV Basics Author: Tricia Smith, Canadian AIDS Treatment Information Exchange 1 Disclaimer Decisions about particular medical treatments
More informationHIV Integrase Inhibitors: Current and Future Use. Douglas G. Fish, MD Albany Medical College Cali, Colombia March 13, 2008
HIV Integrase Inhibitors: Current and Future Use Douglas G. Fish, MD Albany Medical College Cali, Colombia March 13, 2008 Which of the following statements about raltegravir is false? a) Raltegravir is
More informationHIV Drug Market by Medication class (multi-class combination drugs, nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse
HIV Drug Market by Medication class (multi-class combination drugs, nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), protease inhibitors (PIs),
More informationPHARMACOKINETICS OF ANTIRETROVIRAL AND ANTI-HCV AGENTS
8. PHARMACOKINETICS OF ANTIRETROVIRAL AND ANTI-HCV AGENTS David Burger José Moltó Table 8.1a: INFLUENCE OF FOOD ON ABSORPTION (AREA UNDER THE CURVE) OF ANTIRETROVIRAL AGENTS NUCLEOSIDE ANALOGUES NtRTI
More informationHIV/AIDS Update 2007
HIV/AIDS Update 2007 Joanne J. Orrick, Pharm.D., BCPS Clinical Assistant Professor University of Florida Faculty, Florida/Caribbean AIDS Education and Training Center orricjj@ufl.edu www.faetc.org orricjj@ufl.edu
More informationHIV in the Workplace
OEM012_CH24.qxp 8/6/08 12:00 PM Page 441 24 HIV in the Workplace Alan L. Williams and Richard J. Thomas* Over 25 years have elapsed since the first cases of what would become known as the acquired immune
More informationHIV in the United States: At A Glance
HIV / AIDS Overview HIV in the United States: At A Glance November 2013 Fast Facts More than 1.1 million people in the United States are living with HIV infection, and almost 1 in 6 (15.8%) are unaware
More informationHIV Today: Examining the Latest Treatment Advances, Barriers to Care, and Pharmacists Implications
HIV Today: Examining the Latest Treatment Advances, Barriers to Care, and Pharmacists Implications Humberto R. Jimenez, PharmD, BCPS, AAHIVP Comprehensive Pharmacy Services Clinical Pharmacy Specialist
More informationMatters of the HAART: An Update on Current Treatment Options for HIV
Matters of the HAART: An Update on Current Treatment Options for HIV Jason Alegro, PharmD, BCPS Assistant Professor of Clinical Sciences, Roosevelt University Infectious Diseases Clinical Pharmacy Specialist,
More informationSelecting an Initial Antiretroviral Therapy (ART) Regimen
Selecting an Initial Antiretroviral Therapy (ART) Regimen An HIV Diagnosis is a Call to Action In support of the NYSDOH AIDS Institute s January 2018 call to action for patients newly diagnosed with HIV,
More informationMedication Errors Focus on the HIV-Infected Patient
Medication Errors Focus on the HIV-Infected Patient Nimish Patel, Pharm.D., Ph.D., AAHIVP Associate Professor Albany College of Pharmacy & Health Sciences I do not have any conflict of interest in relation
More informationTreatment of respiratory virus infection Influenza A & B Respiratory Syncytial Virus (RSV)
Treatment of respiratory virus infection Influenza A & B Respiratory Syncytial Virus (RSV) Amantadine and Rimantadine Use is limited to Influenza A infection. Very effective in preventing infection if
More information30 Years of HIV: An Update on Treatment Guidelines and Beyond
8/3/212 Conflict of Interest Declaration 3 Years of HIV: An Update on Treatment Guidelines and Beyond Blake Max, PharmD, AAHIVE Clinical Associate Professor University of Illinois at Chicago College of
More informationHIV Update. Divya Ahuja, MD Associate Professor of Medicine University of South Carolina School of Medicine
HIV Update Divya Ahuja, MD Associate Professor of Medicine University of South Carolina School of Medicine Rates of Diagnoses of HIV Infection among Adults and Adolescents, 2012 United States and 6 Dependent
More informationThe New Agents: Management of Experienced Patients and Resistance. Joel E. Gallant, MD, MPH Johns Hopkins University School of Medicine
The New Agents: Management of Experienced Patients and Resistance Joel E. Gallant, MD, MPH Johns Hopkins University School of Medicine T.D. 45 year old man with HIV infection diagnosed in 2000 On multiple
More informationNATAPNATIONAL. HIV 102: Care & Treatment AIDS TREATMENT ADVOCACY PROJECT. Origins of HIV. Table of Contents. National AIDS Treatment Advocacy Project
National AIDS Treatment Advocacy Project HIV 102: Care & Treatment Written by: Jose Castro, MD University of Miami, Miller School of Medicine, Miami, FL Editorial Contributions by: Jules Levin 580 BROADWAY,
More information